CliffBio
small molecule

ZILBRYSQ

ZILUCOPLAN SODIUM

Loss of exclusivityJune 2035latest FDA-listed patent expiry
CompanyUCB →View the full company profile on CliffBio

Drug detail

Brand nameZILBRYSQ
Active ingredientZILUCOPLAN SODIUM
StrengthEQ 16.6MG BASE/0.416ML (EQ 16.6MG BASE/0.416ML)
Dosage formSOLUTION
RouteSUBCUTANEOUS
ModalitySmall molecule
FDA approvalOctober 2023
Marketing statusRX

Listed patents

PatentExpiresType
11752190June 2035product
11014965June 2035substance
10435438June 2035substance
10208089June 2035substance
10106579June 2035substance, product
10835574June 2035product
11535650June 2035product
10562934June 2035substance
11965040June 2035product

Regulatory exclusivity

CodeExpires
ODE-446October 2030
NCEOctober 2028

More from UCB

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ZILBRYSQ patent cliff — loss of exclusivity June 2035 | CliffBio